Public Profile

Salix Pharmaceuticals, Inc.

Salix Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and focuses primarily on gastrointestinal (GI) disorders. Founded in 2001, Salix has established itself as a leader in developing innovative therapies that address unmet medical needs in the GI space. The company’s core products, including treatments for conditions such as irritable bowel syndrome and inflammatory bowel disease, are distinguished by their efficacy and patient-centric approach. With a strong market position, Salix has achieved significant milestones, including the successful launch of several key medications that have transformed patient care. The company’s commitment to research and development, alongside its strategic partnerships, has solidified its reputation as a trusted provider of specialised GI therapies, making it a vital contributor to the healthcare landscape.

DitchCarbon Score

How does Salix Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

30

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Salix Pharmaceuticals, Inc.'s score of 30 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Salix Pharmaceuticals, Inc.'s reported carbon emissions

Salix Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the absence of documented reduction initiatives or climate pledges suggests that the company may still be in the early stages of formalising its climate commitments. As the pharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Salix to establish clear targets and strategies to address climate change and reduce their environmental impact.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Salix Pharmaceuticals, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Salix Pharmaceuticals, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Salix Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Obagi

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Chiesi USA, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Jazz Pharmaceuticals

GB
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Momenta Pharmaceuticals, Inc.

US
Health and social work services (85)
Updated 3 months ago
DitchCarbon Score

Aptalis Holdings Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Sagent Pharmaceuticals, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers